IONS
Price
$31.43
Change
-$0.85 (-2.63%)
Updated
Jan 17 closing price
Capitalization
4.96B
32 days until earnings call
REGN
Price
$681.58
Change
-$11.65 (-1.68%)
Updated
Jan 17 closing price
Capitalization
74.9B
17 days until earnings call
Ad is loading...

IONS vs REGN

Header iconIONS vs REGN Comparison
Open Charts IONS vs REGNBanner chart's image
Ionis Pharmaceuticals
Price$31.43
Change-$0.85 (-2.63%)
Volume$1.37M
Capitalization4.96B
Regeneron Pharmaceuticals
Price$681.58
Change-$11.65 (-1.68%)
Volume$1.11M
Capitalization74.9B
IONS vs REGN Comparison Chart
Loading...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IONS vs. REGN commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a Hold and REGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (IONS: $31.43 vs. REGN: $681.58)
Brand notoriety: IONS: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IONS: 87% vs. REGN: 127%
Market capitalization -- IONS: $4.96B vs. REGN: $74.9B
IONS [@Biotechnology] is valued at $4.96B. REGN’s [@Biotechnology] market capitalization is $74.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IONS’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 0 green FA rating(s).

  • IONS’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than IONS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IONS’s TA Score shows that 2 TA indicator(s) are bullish while REGN’s TA Score has 3 bullish TA indicator(s).

  • IONS’s TA Score: 2 bullish, 4 bearish.
  • REGN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than IONS.

Price Growth

IONS (@Biotechnology) experienced а -6.07% price change this week, while REGN (@Biotechnology) price change was -2.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

IONS is expected to report earnings on Apr 30, 2025.

REGN is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($74.9B) has a higher market cap than IONS($4.96B). REGN YTD gains are higher at: -4.317 vs. IONS (-10.097). REGN has higher annual earnings (EBITDA): 5.5B vs. IONS (-249.52M). REGN has more cash in the bank: 9.8B vs. IONS (2.48B). IONS has less debt than REGN: IONS (1.45B) vs REGN (2.7B). REGN has higher revenues than IONS: REGN (13.8B) vs IONS (803M).
IONSREGNIONS / REGN
Capitalization4.96B74.9B7%
EBITDA-249.52M5.5B-5%
Gain YTD-10.097-4.317234%
P/E RatioN/A16.86-
Revenue803M13.8B6%
Total Cash2.48B9.8B25%
Total Debt1.45B2.7B54%
FUNDAMENTALS RATINGS
IONS vs REGN: Fundamental Ratings
IONS
REGN
OUTLOOK RATING
1..100
687
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
9851
PRICE GROWTH RATING
1..100
8865
P/E GROWTH RATING
1..100
7291
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (66) in the Biotechnology industry is in the same range as IONS (96). This means that REGN’s stock grew similarly to IONS’s over the last 12 months.

REGN's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for IONS (100). This means that REGN’s stock grew somewhat faster than IONS’s over the last 12 months.

REGN's SMR Rating (51) in the Biotechnology industry is somewhat better than the same rating for IONS (98). This means that REGN’s stock grew somewhat faster than IONS’s over the last 12 months.

REGN's Price Growth Rating (65) in the Biotechnology industry is in the same range as IONS (88). This means that REGN’s stock grew similarly to IONS’s over the last 12 months.

IONS's P/E Growth Rating (72) in the Biotechnology industry is in the same range as REGN (91). This means that IONS’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IONSREGN
RSI
ODDS (%)
N/A
Bullish Trend 11 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 11 days ago
66%
Bearish Trend 11 days ago
57%
Momentum
ODDS (%)
N/A
Bullish Trend 11 days ago
67%
MACD
ODDS (%)
Bearish Trend 11 days ago
72%
N/A
TrendWeek
ODDS (%)
Bearish Trend 11 days ago
69%
Bullish Trend 11 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 11 days ago
70%
Bearish Trend 11 days ago
61%
Advances
ODDS (%)
Bullish Trend 26 days ago
61%
Bullish Trend 11 days ago
63%
Declines
ODDS (%)
Bearish Trend 20 days ago
70%
Bearish Trend 20 days ago
51%
BollingerBands
ODDS (%)
N/A
Bearish Trend 11 days ago
56%
Aroon
ODDS (%)
Bearish Trend 11 days ago
72%
Bearish Trend 11 days ago
63%
View a ticker or compare two or three
Ad is loading...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HAPY24.300.51
+2.15%
Harbor Human Capital Factor Uncons ETF
AESR17.700.12
+0.68%
Anfield US Equity Sector Rotation ETF
RETL9.400.06
+0.64%
Direxion Daily Retail Bull 3X ETF
KOMP52.500.19
+0.36%
SPDR® S&P Kensho New Economies Comps ETF
KBWP114.86-1.09
-0.94%
Invesco KBW Property & Casualty Ins ETF

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with IDYA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-1.68%
IDYA - REGN
41%
Loosely correlated
-2.38%
MTNB - REGN
41%
Loosely correlated
+3.02%
TECH - REGN
40%
Loosely correlated
-0.35%
VRTX - REGN
37%
Loosely correlated
+1.21%
INVA - REGN
36%
Loosely correlated
+0.70%
More